Request availability and a quotation for your required quantity and destination.
| Product | Tirzepatide 2.5 mg - Mounjaro Vial |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Mounjaro contains tirzepatide, a once-weekly injectable dual GIP/GLP-1 receptor agonist. The 2.5 mg vial is a labeled strength used in clinician-supervised type 2 diabetes care. U.S. Mounjaro labeling is for glycaemic management in type 2 diabetes, not a standalone weight-loss indication; approved indications differ by country.
It improves glycaemic control alongside dietary changes and exercise in adults with type 2 diabetes. Treatment choice depends on health history, co-prescribed medicines, adverse effects and approved local labeling.
Tirzepatide activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It can support glucose-dependent insulin secretion, lower glucagon and reduce food intake.
The 2.5 mg weekly dose is normally the initiation dose for the first four weeks and is not intended for glycaemic control alone. Prescribers generally increase to 5 mg after that period as appropriate. A single-dose vial requires correct professional training and an appropriate syringe; do not reuse or share.
Common effects include nausea, diarrhoea, vomiting, constipation and abdominal discomfort. Important warnings include pancreatitis, gallbladder complications, kidney injury linked to dehydration, severe gastrointestinal effects and hypoglycaemia with certain diabetes medicines. U.S. labeling has a boxed warning for thyroid C-cell tumors in rats and contraindicates use with a personal/family history of medullary thyroid carcinoma or MEN2. Discuss pregnancy, oral contraceptive effectiveness and planned anesthesia with the prescriber.
Mounjaro 2.5 mg vial and Mounjaro 5 mg vial are separate presentations. Review the labeled instructions for each rather than treating them as interchangeable.
U.S. FDA Mounjaro prescribing information (2026) includes vial instructions, approved uses and boxed warnings.
No. Have a qualified professional check your diagnosis, medical history, other medications and the exact product leaflet.
Enquiries can be submitted, but availability and any supply depend on prescription requirements, destination-country rules and documentation.
Cureiva Healthcare offers product information and enquiry support, not a medical diagnosis. No personal clinician sign-off is claimed. Medical information checked against the linked references in October 2026.